Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:APVO NASDAQ:GRTX NYSE:OGEN NASDAQ:TCRT On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeAPVOAptevo Therapeutics$1.50+4.2%$2.30$1.40▼$381.10$4.93M5.771.55 million shs114.04 million shsGRTXGalera Therapeutics$0.02+1.7%$0.02$0.02▼$0.08$1.34M1.989,898 shs26,069 shsOGENOragenics$1.30+2.4%$1.23$1.01▼$18.90$5.37M0.82307,943 shs145,153 shsTCRTAlaunos Therapeutics$2.36+4.7%$2.74$1.31▼$6.20$5.21M-0.82229,924 shs25,256 shs5G Stocks: The Path Forward is ProfitableEnter your email address and we'll send you MarketBeat's guide to investing in 5G and which 5G stocks show the most promise. Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceAPVOAptevo Therapeutics-2.04%-2.70%-28.00%-48.94%-99.99%GRTXGalera Therapeutics-18.60%+7.36%-22.22%-37.50%-74.26%OGENOragenics+4.96%+8.55%+10.43%-70.94%-92.00%TCRTAlaunos Therapeutics-2.60%+2.74%0.00%-38.52%-3.43%Compare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeAPVOAptevo Therapeutics$1.50+4.2%$2.30$1.40▼$381.10$4.93M5.771.55 million shs114.04 million shsGRTXGalera Therapeutics$0.02+1.7%$0.02$0.02▼$0.08$1.34M1.989,898 shs26,069 shsOGENOragenics$1.30+2.4%$1.23$1.01▼$18.90$5.37M0.82307,943 shs145,153 shsTCRTAlaunos Therapeutics$2.36+4.7%$2.74$1.31▼$6.20$5.21M-0.82229,924 shs25,256 shs5G Stocks: The Path Forward is ProfitableEnter your email address and we'll send you MarketBeat's guide to investing in 5G and which 5G stocks show the most promise. Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceAPVOAptevo Therapeutics-2.04%-2.70%-28.00%-48.94%-99.99%GRTXGalera Therapeutics-18.60%+7.36%-22.22%-37.50%-74.26%OGENOragenics+4.96%+8.55%+10.43%-70.94%-92.00%TCRTAlaunos Therapeutics-2.60%+2.74%0.00%-38.52%-3.43%Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceAPVOAptevo Therapeutics 3.00Buy$219,040.0014,602,566.67% UpsideGRTXGalera Therapeutics 0.00N/AN/AN/AOGENOragenics 0.00N/AN/AN/ATCRTAlaunos Therapeutics 0.00N/AN/AN/ACurrent Analyst Ratings BreakdownCompare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookAPVOAptevo TherapeuticsN/AN/AN/AN/A$65.21 per shareN/AGRTXGalera TherapeuticsN/AN/AN/AN/A($2.41) per shareN/AOGENOragenicsN/AN/AN/AN/A$0.61 per shareN/ATCRTAlaunos Therapeutics$10K520.46N/AN/A$1.29 per share1.83Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateAPVOAptevo Therapeutics-$24.13MN/A0.00N/AN/AN/A-675.52%-175.68%11/6/2025 (Estimated)GRTXGalera Therapeutics-$59.08M-$0.19N/A∞N/AN/AN/A-99.34%N/AOGENOragenics-$20.66M-$21.42N/A∞N/AN/A-2,087.95%-486.56%N/ATCRTAlaunos Therapeutics-$4.68M-$2.46N/A∞N/AN/A-168.02%-121.37%11/12/2025 (Estimated)Latest GRTX, APVO, TCRT, and OGEN EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails8/14/2025Q2 2025TCRTAlaunos Therapeutics-$5.3340-$0.63+$4.7040-$0.63N/AN/A8/11/2025Q2 2025APVOAptevo Therapeutics-$83.20-$8.40+$74.80-$8.40N/AN/ACompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthAPVOAptevo TherapeuticsN/AN/AN/AN/AN/AGRTXGalera TherapeuticsN/AN/AN/AN/AN/AOGENOragenicsN/AN/AN/AN/AN/ATCRTAlaunos TherapeuticsN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioAPVOAptevo TherapeuticsN/A2.272.27GRTXGalera TherapeuticsN/A9.749.74OGENOragenicsN/A1.931.93TCRTAlaunos TherapeuticsN/A3.483.48Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipAPVOAptevo Therapeutics8.06%GRTXGalera Therapeutics50.77%OGENOragenics18.71%TCRTAlaunos Therapeutics27.72%Insider OwnershipCompanyInsider OwnershipAPVOAptevo Therapeutics0.01%GRTXGalera Therapeutics12.90%OGENOragenics4.90%TCRTAlaunos Therapeutics16.14%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableAPVOAptevo Therapeutics503.29 million3.28 millionNot OptionableGRTXGalera Therapeutics3075.46 million47.38 millionOptionableOGENOragenics54.13 million10.98 millionN/ATCRTAlaunos Therapeutics402.21 million1.85 millionNo DataGRTX, APVO, TCRT, and OGEN HeadlinesRecent News About These CompaniesAlaunos Therapeutics, Inc. (NASDAQ:TCRT) Short Interest UpdateSeptember 12, 2025 | americanbankingnews.comAlaunos Therapeutics files $50M mixed securities shelfAugust 21, 2025 | msn.comAlaunos Therapeutics files $50M mixed securities shelfAugust 21, 2025 | msn.comAlaunos Therapeutics’ Innovative Glioblastoma Study Completes: Market ImplicationsAugust 12, 2025 | msn.comAlaunos Therapeutics Appoints Holger Weis as New CEOJuly 25, 2025 | theglobeandmail.comAlaunos Therapeutics Taps Board Member Weis as Next CEOJuly 2, 2025 | marketwatch.comAlaunos Therapeutics, Inc. (TCRT) - Yahoo FinanceJune 26, 2025 | finance.yahoo.comAlaunos Therapeutics Raises $850,000 in Private OfferingJune 26, 2025 | tipranks.comAlaunos Therapeutics Announces $2.0 Million Registered Direct Offering - MorningstarJune 24, 2025 | morningstar.comMAlaunos Therapeutics Announces $2.0 Million Registered Direct OfferingJune 23, 2025 | globenewswire.comAlaunos Therapeutics Amends Warrant Agreement with Mast HillJune 10, 2025 | tipranks.comPMGC Capital LLC, a Subsidiary of PMGC Holdings Inc. (Nasdaq: ELAB), To File Schedule 13D Reporting 5.09% Stake in Alaunos Therapeutics, Inc. (Nasdaq: TCRT)May 14, 2025 | globenewswire.comAlaunos Therapeutics announces board member resignationApril 20, 2025 | investing.comThese 3 Healthcare Stocks Show Serious Muscle Amid Trump Tariff Turmoil: Are Retail Traders Feeling Bullish?April 7, 2025 | msn.comPrecigen Terminates License Agreement With Alaunos TherapeuticsOctober 11, 2024 | marketwatch.comAfter axing its sole clinical prospect last year, Alaunos cuts ties with PrecigenOctober 11, 2024 | fiercebiotech.comFAlaunos Therapeutics Ends Licensing Deal, Reassesses StrategyOctober 11, 2024 | finance.yahoo.comAlaunos Therapeutics (NASDAQ:TCRT) Stock, Short Interest ReportSeptember 26, 2024 | benzinga.comAlaunos Therapeutics (NASDAQ:TCRT) Stock Quotes, Forecast and News SummarySeptember 26, 2024 | benzinga.comStella Pharma Corporation (4888.T) Stock Price, News, Quote & History - Yahoo FinanceSeptember 24, 2024 | finance.yahoo.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeGRTX, APVO, TCRT, and OGEN Company DescriptionsAptevo Therapeutics NASDAQ:APVO$1.50 +0.06 (+4.17%) Closing price 04:00 PM EasternExtended Trading$1.54 +0.04 (+2.93%) As of 06:49 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Aptevo Therapeutics Inc., a clinical-stage research and development biotechnology company, focuses on developing immunotherapeutic candidates for the treatment of various forms of cancer in the United States. It develops its products using ADAPTIR and ADAPTIR-FLEX platforms to generate monospecific, bispecific, and multi-specific antibody candidates capable of enhancing the human immune system against cancer cells. The company's lead clinical blood cancer candidate is APVO436 that is in Phase 1b/2 clinical trial for acute myelogenous leukemia. It is also developing ALG.APV-527, a novel investigational bispecific ADAPTIR candidate that is in Phase 1 clinical trial for NSCLC, head and neck, colorectal, pancreatic, breast, and other solid tumors; APVO603, a preclinical dual agonist bispecific ADAPTIR candidate for multiple solid tumors; APVO442, a novel bispecific candidate based on the ADAPTIR-FLEX platform technology for multiple solid tumors; and APVO711, a preclinical dual mechanism bispecific ADAPTIR candidate for prostate cancer. The company has a collaboration and option agreement with Alligator Bioscience AB to develop ALG.APV-527. Aptevo Therapeutics Inc. was incorporated in 2016 and is headquartered in Seattle, Washington.Galera Therapeutics NASDAQ:GRTX$0.02 +0.00 (+1.71%) As of 03:12 PM EasternGalera Therapeutics, Inc., a biopharmaceutical company, focuses on the development and commercialization of therapeutics for the transformation of radiotherapy in cancer. The company's lead product candidate is avasopasem manganese (GC4419), a small molecule dismutase mimetic for the treatment of radiotherapy induced severe oral mucositis in patients with head and neck cancer (HNC); for the treatment of radiotherapy-induced esophagitis in patients with lung cancer; and for patients with HNC undergoing standard-of-care radiotherapy. It also develops rucosopasem manganese (rucosopasem) to augment the anti-cancer efficacy of stereotactic body radiation therapy in patients with non-small cell lung cancer and locally advanced pancreatic cancer. The company was incorporated in 2012 and is based in Malvern, Pennsylvania.Oragenics NYSE:OGEN$1.30 +0.03 (+2.36%) Closing price 04:00 PM EasternExtended Trading$1.27 -0.03 (-1.92%) As of 06:42 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Oragenics, Inc., a development-stage company, engages in the research and development of antibiotics for infectious diseases in the United States. The company engages in the development and commercialization of NT-CoV2-1, an intranasal vaccine candidate that provides immunity from the novel severe acute respiratory syndrome coronavirus. The company's product candidates also comprise LPT3-04, a weight loss candidate; and SMaRT Replacement Therapy, a topical treatment to prevent dental carries. It has a license agreement with Noachis Terra Inc. for licensing of certain specified patent rights and biological materials relating to the use of pre-fusion coronavirus spike proteins; and a collaboration agreement ILH Holdings, Inc. for the development and commercialization of MU1140 and related homologs. The company was formerly known as Oragen, Inc. Oragenics, Inc. was incorporated in 1996 and is headquartered in Tampa, Florida.Alaunos Therapeutics NASDAQ:TCRT$2.36 +0.11 (+4.67%) Closing price 03:58 PM EasternExtended Trading$2.31 -0.04 (-1.91%) As of 06:25 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Alaunos Therapeutics, Inc., a clinical-stage oncology-focused cell therapy company, develops adoptive T-cell receptor (TCR) engineered T-cell therapies (TCR-T) to treat multiple solid tumor types. It develops Library TCR-T Cell Theraphy, which is in Phase I/II clinical trial for 12 TCRs reactive to mutated KRAS, TP53, and EGFR from its TCR library for the treatment of non-small cell lung, colorectal, endometrial, pancreatic, ovarian, and bile duct cancers. The company is also developing hunTR, a human neoantigen TCR discovery engine; and Sleeping Beauty Gene Transfer Platform, a non-viral genetic engineering technology. The company was founded in 2003 and is headquartered in Houston, Texas. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Resideo Technologies: Institutional Activity Signals 30% Upside Lululemon’s Sell-Off Looks Overdone: A Contrarian Case Palantir’s Commercial Growth Story Is Just Getting Started How Bath & Body Works Is a Perfect Example of a Value Stock The Applied Digital Breakout Is Only the Beginning $100 Million Buyback in Upwork Stock Follows a Strong Quarter Uranium Energy Stock Has Momentum—and More Upside Ahead Why Opendoor Stock Is Soaring—and May Just Be Starting Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
